Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 6/20 | 0.35 |
| ▸ | IDH2 | P48735 | 5/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 2/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.30 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL304987 | 0.82 | CYP3A4 (0.33) | — | |
| SCHEMBL152217 | 0.82 | — | — | |
| SCHEMBL1182091 | 0.79 | NOS3 (0.35) | IDH1 | |
| SCHEMBL2490012 | 0.78 | BTK (0.31) | — | |
| SCHEMBL3559087 | 0.75 | SOS2 (0.33) | — | |
| SCHEMBL18580969 | 0.74 | — | — | |
| SCHEMBL15201656 | 0.73 | TRPV4 (0.39) | P2RX7 | |
| SCHEMBL16290728 | 0.73 | P2RX7 (0.43) | ADRB1IDH1IDH2P2RX7NOTUM | |
| SCHEMBL29366156 | 0.73 | P2RX7 (0.43) | ADRB1IDH1IDH2P2RX7NOTUM | |
| SCHEMBL4258665 | 0.73 | CD38 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136598-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-01 | — | — | US | disclosed |
| US-12172997-B2 | Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-24 | — | — | US | disclosed |
| WO-2023134686-A1 | PREPARATION METHOD FOR 1,3,5-TRIAZINE DERIVATIVE | 正大天晴药业集团股份有限公司 | 2023-07-20 | — | — | WO | disclosed |
| US-20230151006-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-18 | — | — | US | disclosed |
| US-11618750-B2 | Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-04 | — | — | US | disclosed |
| EP-3983075-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2022-04-20 | — | — | EP | disclosed |
| US-20210017168-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-21 | — | — | US | disclosed |
| WO-2020249792-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | WO | disclosed |
| EP-2785707-B1 | NOVEL 2H-INDAZOLES AS EP2 RECEPTOR ANTAGONISTS | BAYER IP GMBH (DE) | 2018-01-24 | — | — | EP | disclosed |
| US-9655887-B2 | Pharmaceutical composition and the use thereof, and application regime of said pharmaceutical composition for on-demand contraception | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-05-23 | — | — | US | disclosed |
| EP-2212287-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | Janssen Pharmaceutica, N.V. (BE) | 2010-08-04 | — | — | EP | disclosed |
| EP-2209764-A1 | GSM INTERMEDIATES | Janssen Pharmaceutica, N.V. (BE) | 2010-07-28 | — | — | EP | disclosed |
| US-7727988-B2 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | GLAXO GROUP LIMITED (GB) | 2010-06-01 | — | — | US | disclosed |
| US-20090306392-A1 | GSM INTERMEDIATES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-12-10 | — | — | US | disclosed |
| WO-2009052341-A1 | GSM INTERMEDIATES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009052126-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF γ-SECRETASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-23 | — | — | WO | disclosed |
| US-20090105275-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-23 | — | — | US | disclosed |
| EP-2007750-A1 | AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2008-12-31 | — | — | EP | disclosed |
| US-20070249642-A1 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| WO-2007113232-A1 | AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105275-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | BACE1, BACE2, PSEN1 | ADRB1 1664/4885IDH1 3232/4885IDH2 3467/4885 |
| US-20090306392-A1 | GSM INTERMEDIATES | BACE1, GSAP, PSEN1 | ADRB1 764/4885IDH1 299/4885IDH2 234/4885 |
| US-12172997-B2 | Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators | GRIN2B, GRIN2A, GRIN3A | ADRB1 255/4885IDH1 2565/4885IDH2 1747/4885 |
| US-20230151006-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR | GRIN2B, GRIN2A, GRIN3A | ADRB1 293/4885IDH1 1999/4885IDH2 1384/4885 |
| US-20250136598-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3A | ADRB1 255/4885IDH1 2565/4885IDH2 1747/4885 |
| US-11618750-B2 | Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators | GRIN2B, GRIN2A, GRIN3A | ADRB1 255/4885IDH1 2565/4885IDH2 1747/4885 |
| US-20210017168-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3A | ADRB1 255/4885IDH1 2565/4885IDH2 1747/4885 |
| US-20070249642-A1 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | AZI2, NT5C3B, CYP1B1 | ADRB1 1098/4885IDH1 124/4885IDH2 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.